PDCD1 and hepatocellular carcinoma: However, most existing work has focused on single checkpoint targets, and the therapeutic potential of dual checkpoint blockade within a single oncolytic vaccinia vector—particularly combining PD-1 inhibition with novel co-inhibitory target blockade—remains largely unexplored in HCC (8, 10, 11).